The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | An insight into the changing role of transplantation for myeloma & lymphoma in the era of CAR-T
Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, provides insight into the role of allogeneic and autologous stem cell transplantation (autoSCT and alloSCT, respectively) for myeloma and lymphoma in the era of novel immunotherapies, including CAR T-cell therapy and bispecific antibodies. The role of SCT is being challenged in multiple myeloma, as CAR-T trials have shown impressive overall response rates (ORR), complete remission (CR), and progression-free survival (PFS). In diffuse large B-cell lymphoma (DLBCL), CAR T-cell therapy has become the standard of care for patients with primary refractory disease, while autoSCT is still used in late relapse. In follicular lymphoma (FL), the rates of autoSCT and alloSCT have decreased significantly with the advent of novel immunotherapies. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Consultancy, Honoraria, Research Funding, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Research Funding; MSD: Consultancy, Honoraria; Kite: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Jannsen: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; GenMab: Consultancy, Honoraria; Pierre Fabre: Consultancy, Honoraria; Astra Zeneca: Consultancy, Honoraria.
